Prognostic evaluation of preoperative serum C-reactive protein concentration in patients with epithelial ovarian cancer

Lu,Yaping; Huang,Sen; Li,Ping; Chen,Bingyu; Liu,Weiling; Chen,Zhiqing; Yin,Fubo

doi:10.3892/etm.2015.2350

Prognostic evaluation of preoperative serum C-reactive protein concentration in patients with epithelial ovarian cancer

Authors:
- Yaping Lu
- Sen Huang
- Ping Li
- Bingyu Chen
- Weiling Liu
- Zhiqing Chen
- Fubo Yin
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Haimen City People's Hospital, Haimen, Jiangsu 226100, P.R. China, Department of Obstetrics and Gynecology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: March 12, 2015 https://doi.org/10.3892/etm.2015.2350
Pages: 2003-2007

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate correlations between preoperative C‑reactive protein (CRP) serum concentration and the clinical‑pathological parameters of epithelial ovarian cancer (EOC), as well as cancer antigen 125 (CA125) concentration, in patients with EOC. The preoperative serum CRP concentrations of 107 patients with EOC were compared with values of 44 control patients and defined as positive if values were >8 mg/l. Correlations between CRP expression and serum CA125 concentrations, International Federation of Gynecologists and Obstetricians (FIGO) staging, lymph node metastasis, ascites and size of postoperative residual lesions were evaluated for the EOC cases. A total of 69% (74/107) of the EOC cases were CRP‑positive, with a mean serum CRP concentration of 14.32 mg/l (versus 2.18 mg/l in the control patients) (P<0.001). A rank correlation analysis showed a positive correlation between serum CRP and CA125 concentrations (P<0.001). The five‑year survival rate of the CRP‑positive patients with EOC was significant lower than that of the patients that were CRP‑negative (33.3 vs. 75.8%, P<0.001). Non‑parametric and multivariate analyses showed significant correlations between CRP concentrations and FIGO staging (P=0.001), lymph node metastasis (P=0.001) and ascites (P=0.033). In contrast to previous reports, the mean CRP serum concentration of the CRP‑positive patients with EOC also correlated significantly with the CA125 values, and the increases in the CRP serum concentration in the Chinese patients were lower than those described for Caucasian EOC cases. In conclusion, the CRP serum concentration may be a useful clinical marker, solely or in combination with CA125, in patients with EOC.

View Figures

View References

1	Wong KH, Mang OW, Au KH and Law SC: . Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study. Hong Kong Med J. 18:466–474. 2012.PubMed/NCBI
2	Helzlsouer KJ, Erlinger TP and Platz EA: C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer. 42:704–707. 2006. View Article : Google Scholar : PubMed/NCBI
3	Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
4	Hefler LA, Zeillinger R, Grimm C, et al: Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 103:512–517. 2006. View Article : Google Scholar : PubMed/NCBI
5	Tempfer C, Zeisler H, Sliutz G, et al: Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol. 66:27–30. 1997. View Article : Google Scholar : PubMed/NCBI
6	Zeimet AG, Widschwendter M, Knabbe C, et al: Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol. 16:1861–1868. 1998.PubMed/NCBI
7	Friedlander ML: Prognostic factors in ovarian cancer. Semin Oncol. 25:305–314. 1998.PubMed/NCBI
8	Winter-Roach BA, Kitchener HC and Lawrie TA: Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 3:CD0047062012.PubMed/NCBI
9	Marchetti CI, Pisano C, Facchini G, et al: First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther. 10:47–60. 2010. View Article : Google Scholar : PubMed/NCBI
10	Marnell L, Mold C and Du Clos TW: C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 117:104–111. 2005. View Article : Google Scholar : PubMed/NCBI
11	Allavena P, Garlanda C, Borrello MG, Sica A and Mantovani A: Pathways connecting inflammation and cancer. Curr Opin Genet Dev. 18:3–10. 2008. View Article : Google Scholar : PubMed/NCBI
12	Lundin E, Dossus L, Clendenen T, et al: C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control. 20:1151–1159. 2009. View Article : Google Scholar : PubMed/NCBI
13	Siemes C, Visser LE, Coebergh JW, et al: C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 24:5216–5222. 2006. View Article : Google Scholar : PubMed/NCBI
14	Il'yasova D, Colbert LH, Harris TB, et al: Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 14:2413–2418. 2005. View Article : Google Scholar : PubMed/NCBI
15	Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A and Boffetta P: Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 15:381–384. 2006. View Article : Google Scholar : PubMed/NCBI
16	Gockel I, Dirksen K, Messow CM and Junginger T: Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol. 12:3746–3750. 2006.PubMed/NCBI
17	Hashimoto K, Ikeda Y, Korenaga D, et al: The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 103:1856–1864. 2005. View Article : Google Scholar : PubMed/NCBI
18	McMillan DC, Canna K and McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 90:215–219. 2003. View Article : Google Scholar : PubMed/NCBI
19	Brown DJ, Milroy R, Preston T and McMillan DC: The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol. 60:705–708. 2007. View Article : Google Scholar : PubMed/NCBI
20	Polterauer S, Grimm C, Tempfer C, et al: C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol. 107:114–117. 2007. View Article : Google Scholar : PubMed/NCBI
21	Anastasi E, Marchei GG, Viggiani V, et al: HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 31:113–119. 2010. View Article : Google Scholar : PubMed/NCBI
22	Klug TL, Bast RC Jr, Niloff JM, Knapp RC and Zurawski VR Jr.: Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 44:1048–1053. 1984.PubMed/NCBI
23	Schilthuis MS, Aalders JG, Bouma J, et al: Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second-look operations and their role in the detection of tumour recurrence. Br J Obstet Gynaecol. 94:202–207. 1987. View Article : Google Scholar : PubMed/NCBI
24	Santillan A, Garg R, Zahurak ML, et al: Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 23:9338–9343. 2005. View Article : Google Scholar : PubMed/NCBI
25	Howe HL, Tung KH, Coughlin S, Jean-Baptiste R and Hotes J: Race/ethnic variations in ovarian cancer mortality in the United States, 1992–1997. Cancer. 97(10 Suppl): 2686–2693. 2003. View Article : Google Scholar : PubMed/NCBI
26	Benedet JL, Bender H, Jones H III, Ngan HY and Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 70:209–262. 2000. View Article : Google Scholar : PubMed/NCBI
27	McSorley MA, Alberg AJ, Allen DS, et al: C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 109:933–941. 2007. View Article : Google Scholar : PubMed/NCBI
28	Ness RB: Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol. 189:280–294. 2003. View Article : Google Scholar : PubMed/NCBI
29	Tung KH, Wilkens LR, Wu AH, et al: Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol. 161:321–329. 2005. View Article : Google Scholar : PubMed/NCBI
30	Shacter E and Weitzman SA: Chronic inflammation and cancer. Oncology (Williston Park). 16:217–226. 2002.PubMed/NCBI
31	McMillan DC, Elahi MM, Sattar N, et al: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 41:64–69. 2001. View Article : Google Scholar : PubMed/NCBI
32	Hefler LA, Concin N, Hofstetter G, et al: Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 14:710–714. 2008. View Article : Google Scholar : PubMed/NCBI
33	Hefler-Frischmuth K, Hefler LA, Heinze G, et al: Serum C-reactive protein in the differential diagnosis of ovarian masses. Eur J Obstet Gynecol Reprod Biol. 147:65–68. 2009. View Article : Google Scholar : PubMed/NCBI
34	Lu Y, Yin F and Chen Z: Prognostic value of preoperative serum C-reactive protein in patients with epithelial ovarian cancer. Progress inObstetrics and Gynecology. 17:489–492. 2008.